Intellipharmaceutics International Inc (IPCI)

0.170
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.165/0.175
  • Day's Range:
    0.170 - 0.170
  • Type:Equity
  • Market:Canada
  • ISIN:CA4581733090
  • CUSIP:458173309

IPCI Overview

Prev. Close
0.18
Day's Range
0.17-0.17
Revenue
371.01K
Open
0.17
52 wk Range
0.155-0.6
EPS
-0.21
Volume
0
Market Cap
5.63M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
6,366
P/E Ratio
-
Beta
1.14
1-Year Change
-22.73%
Shares Outstanding
33,092,665
Next Earnings Date
-
What is your sentiment on Intellipharmaceutics International Inc?
or
Vote to see community's results!

Intellipharmaceutics International Inc News

Intellipharmaceutics International Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellSellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Intellipharmaceutics International Inc Company Profile

Intellipharmaceutics International Inc Company Profile

Employees
33
Market
Canada

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Read More
  • looking good for approval
    0
    • looking good for approval
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.